Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Receives $173.07 Consensus Price Target from Analysts

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has received a consensus recommendation of “Moderate Buy” from the fourteen ratings firms that are currently covering the company, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating and eleven have issued a buy rating on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $173.07.

A number of equities research analysts have recently commented on the stock. Royal Bank of Canada reduced their target price on shares of Jazz Pharmaceuticals from $175.00 to $174.00 and set an “outperform” rating for the company in a research report on Thursday, August 1st. Wells Fargo & Company decreased their target price on shares of Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating on the stock in a research note on Thursday, August 1st. Morgan Stanley dropped their price target on Jazz Pharmaceuticals from $160.00 to $150.00 and set an “equal weight” rating for the company in a research report on Friday, July 12th. The Goldman Sachs Group assumed coverage on Jazz Pharmaceuticals in a research report on Wednesday, June 5th. They set a “buy” rating and a $169.00 price objective on the stock. Finally, Robert W. Baird dropped their target price on Jazz Pharmaceuticals from $160.00 to $154.00 and set an “outperform” rating for the company in a report on Thursday, August 1st.

Jazz Pharmaceuticals Price Performance

NASDAQ:JAZZ opened at $110.93 on Wednesday. The stock has a 50 day moving average of $111.02 and a two-hundred day moving average of $110.79. Jazz Pharmaceuticals has a 12 month low of $99.06 and a 12 month high of $137.38. The firm has a market cap of $7.00 billion, a P/E ratio of 22.87, a price-to-earnings-growth ratio of 1.36 and a beta of 0.57. The company has a current ratio of 2.37, a quick ratio of 2.02 and a debt-to-equity ratio of 1.36.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 EPS for the quarter, topping the consensus estimate of $3.80 by $0.87. The firm had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1 billion. Jazz Pharmaceuticals had a return on equity of 28.65% and a net margin of 10.10%. On average, analysts expect that Jazz Pharmaceuticals will post 16.03 earnings per share for the current fiscal year.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, SVP Mary Elizabeth Henderson sold 1,410 shares of the company’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $108.30, for a total value of $152,703.00. Following the transaction, the senior vice president now directly owns 14,531 shares in the company, valued at approximately $1,573,707.30. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 4.20% of the company’s stock.

Hedge Funds Weigh In On Jazz Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Rise Advisors LLC lifted its position in shares of Jazz Pharmaceuticals by 2,255.6% during the first quarter. Rise Advisors LLC now owns 212 shares of the specialty pharmaceutical company’s stock worth $26,000 after purchasing an additional 203 shares in the last quarter. Versant Capital Management Inc lifted its holdings in Jazz Pharmaceuticals by 13,450.0% during the 2nd quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company’s stock worth $29,000 after buying an additional 269 shares in the last quarter. Itau Unibanco Holding S.A. purchased a new position in Jazz Pharmaceuticals in the 2nd quarter valued at approximately $29,000. EverSource Wealth Advisors LLC grew its stake in shares of Jazz Pharmaceuticals by 55.1% in the second quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock worth $30,000 after acquiring an additional 97 shares in the last quarter. Finally, GAMMA Investing LLC increased its position in shares of Jazz Pharmaceuticals by 65.5% during the second quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock worth $31,000 after acquiring an additional 116 shares during the period. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.